Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 132.85B +33.8% |
| Revenue (ttm) | 12.59B +10.2% |
| Net Income | 4.41B +21.1% |
| EPS | 17.18 +22.1% |
| Shares Out | 253.46M |
| PE Ratio | 29.72 |
| Forward PE | 39.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 468,530 |
| Open | 521.69 |
| Previous Close | 510.72 |
| Day's Range | 508.14 - 525.97 |
| 52-Week Range | 374.17 - 560.25 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 569.19 (+8.6%) |
| Earnings Date | Nov 2, 2026 |
About VRTX
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 31 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price target is $569.19, which is an increase of 8.60% from the latest price.
News
Truist sees ‘significant positive readthrough’ for Maze from Vertex data
Truist analyst Danielle Brill views Vertex’s (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-mediated kidney disease and estimates the data support...
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease...
Vertex Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing a diversified pipeline with global launches in cystic fibrosis, expansion in renal and rare endocrine diseases, and promising assets in acute pain, diabetes, and genetic kidney disorders. Key near-term milestones include pivotal readouts for pove and inaxaplin, and continued rollout of ALYFTREK.
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher
Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.
Vertex Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Recent acquisitions and pipeline progress have diversified the portfolio across five disease pillars, with key milestones ahead in renal, pain, and rare endocrine diseases. Commercial infrastructure has matured, supporting strong product launches and steady growth, especially in pain and specialty endocrinology. Key financial and clinical updates are expected by year-end.
Vertex Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Multiple near-term catalysts are expected, including pivotal renal data, a major IgAN launch, and key readouts in pain and rare diseases. Commercial strategies focus on clinical differentiation, patient access, and global expansion, with a vision for diversified revenue across five therapeutic pillars by 2027.
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pha...
Vertex to Participate in Upcoming September Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investo...
Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.
A few sectors have dominated the market this year, and healthcare isn't one of them. Many stocks in the sector look ready to gain.
Vertex Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 revenue rose 12% year-over-year to $3.3B, led by CF, CASGEVY, and JOURNAVX growth. The company raised full-year guidance, advanced its pipeline, and announced the $8.8B Crinetics acquisition, adding a fifth commercial pillar in rare endocrine diseases.
Vertex Pharmaceuticals Earnings release: Q2 2026
Vertex Pharmaceuticals released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Vertex Pharmaceuticals Slides: Q2 2026
Vertex Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
Vertex Pharmaceuticals Quarterly report: Q2 2026
Vertex Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 3, 2026.
Vertex raises annual revenue forecast on cystic fibrosis drugs strength
Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust demand for its cystic fibrosis treatments.
Vertex Reports Second Quarter 2026 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 rev...
How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks
More mergers among brand-name consumer companies seem likely—following a record $2.6 trillion worth of transactions announced in the first half of 2026.
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The comp...
Crinetics shares surge after Vertex agrees to $10B cash buyout
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-...
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - July 7, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Crinetics Pharmaceutica...
This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal
Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
The acquisition would add to Vertex's pipeline and potentially grow its annual revenue by $5 billion with the addition of Crinetics-developed drugs Palsonify and Atumelnant, the company said.
Vertex Pharmaceuticals Transcript: M&A announcement
Vertex will acquire Crinetics for $85/share in cash (~$10B equity value), adding best-in-class endocrine assets PALSONIFY and atumelnant. The deal diversifies Vertex's portfolio, is expected to deliver over $5B in peak sales, and will be accretive to operating income by 2029.
Vertex Pharmaceuticals Press release: M&A announcement
Vertex Pharmaceuticals issued a press release on July 6, 2026, disclosing material business information to investors.
Vertex Pharmaceuticals Slides: M&A announcement
Vertex Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 6, 2026.
Vertex to buy Crinetics in $10 billion deal
Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity value of about $10 billion, the companies said on Monday.